Eyenovia, Inc. provided a corporate update on its pipeline with recent and upcoming milestones. Eyenovia previously announced initial topline data from its Phase 3 VISION-1 clinical trial, which evaluated the company's proprietary pilocarpine solution, administered via the Optejet, for the treatment of presbyopia. The company is providing additional details from the study. The VISION-1 study evaluated the safety and efficacy of Eyenovia's MicroLine presbyopia microdose formulations versus placebo, all administered via the company's proprietary Optejet delivery Micro-Array Print technology. The VISION-1 study evaluated the safety and efficacy of Eyenovia's 1% and 2% pilocarpine Micro-Array Print (MAP) formulations versus placebo, all administered via the company's proprietary Optejet dispenser. VISION-1 is the third Phase 3 study demonstrating the utility of the company's MAP technology in improving the therapeutic index of topical ophthalmic drugs. To support the submission of a New Drug Application (NDA), the company is on track to initiate a second Phase 3 registrational trial, VISION-2, later this year. VISION-2 will be a double-masked, placebo-controlled, cross-over superiority trial designed to enroll 120 patients randomized between 2% pilocarpine and placebo cohorts. Topline data is anticipated in mid-2022. It is estimated that as many as 18 million people between the ages of 40-55 suffer from presbyopia in the U.S. alone, suggesting a multi-billion-dollar addressable market for MicroLine, if approved.